rethinkTHC Search
Menu
Study breakdown

Prenatal Cannabis Exposure Disrupted Breathing Regulation in Offspring With Sex-Specific Effects Lasting Into Adolescence

Animal StudyModerate evidence
The takeaway

Prenatal exposure to a synthetic cannabinoid disrupted breathing regulation in rat offspring in sex-specific ways: males showed altered CO2 sensitivity and hypoxic responses, while females showed increased spontaneous apnea and reduced serotonin neurons at birth.

Neonatologists, SIDS researchers, prenatal care providers, pregnant cannabis users.

Female offspring showed increased apnea and reduced serotonin neurons, relevant to SIDS risk

What the researchers found

Prenatal WIN55,212-2 caused greater CO2 sensitivity at most ages in males and juvenile females. Males showed altered hypoxic chemoreflex at birth (hyperventilation) and P6-7 (hypoventilation), absent in females. Males had increased catecholaminergic neurons, more CB1 expression, and altered tissue respiration in brainstem. Reduced pulmonary compliance was seen in juvenile males. Females at birth showed enhanced spontaneous apnea and reduced serotonin neurons in raphe magnus.

Why it matters

This is one of the first studies to examine how prenatal cannabinoid exposure affects the developing respiratory system. The sex-specific effects are striking: males show widespread breathing dysregulation while females show a potentially dangerous pattern of spontaneous apnea at birth with reduced serotonin neurons, relevant to SIDS risk.

The numbers in context

Four developmental timepoints assessed. Males: altered CO2 sensitivity at 3 of 4 ages, altered hypoxic response at P0 and P6-7, increased catecholaminergic neurons, reduced pulmonary compliance. Females at P0: enhanced apnea, reduced serotonin neurons in raphe magnus.

How the study worked

Prenatal WIN55,212-2 (0.5 mg/kg/day) administered to pregnant rats. Respiratory function assessed in male and female offspring at four developmental timepoints (P0, P6-7, P12-13, P27-28). Brainstem neurochemistry and pulmonary mechanics also examined.

What this study cannot tell us

Animal study with synthetic cannabinoid at a single dose, which may not reflect human cannabis use patterns. Rat respiratory development differs from humans. Cannot directly extrapolate to SIDS risk.

How to read the evidence

Well-designed developmental animal study with multiple timepoints and sex-specific analysis, but limited translational applicability.

When this study was published

Published 2023.

The bigger picture

The female finding of increased apnea with reduced serotonin neurons is particularly concerning because serotonergic dysfunction in the brainstem is one of the leading hypotheses for SIDS. If prenatal cannabis exposure impairs this system, it could contribute to sudden infant death risk.

Questions still open

  • Does prenatal cannabis exposure contribute to SIDS risk through serotonergic brainstem dysfunction?
  • Are these respiratory effects reversible with postnatal development?

Common questions

Can cannabis use during pregnancy affect the baby's breathing?
In rats, prenatal cannabinoid exposure disrupted breathing regulation in offspring in sex-specific ways that persisted into adolescence, raising concerns about respiratory development.
Is there a link between prenatal cannabis and SIDS?
This animal study found female offspring had increased spontaneous apnea and reduced brainstem serotonin neurons, both of which are relevant to SIDS. Human studies are needed to confirm this connection.

Read the original research

Sex- and age-specific respiratory alterations induced by prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 in rats.

British journal of pharmacology, 180(13), 1766-1789

Citation

Patrone, Luis Gustavo A; Ferrari, Gustavo D; da Silva, Rodrigo Moreira; Alberici, Luciane C; Lopes, Norberto Peporine; Stabile, Angelita M; Klein, Wilfried; Bícego, Kênia C; Gargaglioni, Luciane H. (2023). Sex- and age-specific respiratory alterations induced by prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 in rats.. British journal of pharmacology, 180(13), 1766-1789. https://doi.org/10.1111/bph.16044

Explore the wider topic